Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,904 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The protective effect of Bifidobacterium bifidum G9-1 against mucus degradation by Akkermansia muciniphila following small intestine injury caused by a proton pump inhibitor and aspirin.
Yoshihara T, Oikawa Y, Kato T, Kessoku T, Kobayashi T, Kato S, Misawa N, Ashikari K, Fuyuki A, Ohkubo H, Higurashi T, Tateishi Y, Tanaka Y, Nakajima S, Ohno H, Wada K, Nakajima A. Yoshihara T, et al. Among authors: kobayashi t. Gut Microbes. 2020 Sep 2;11(5):1385-1404. doi: 10.1080/19490976.2020.1758290. Epub 2020 Jun 9. Gut Microbes. 2020. PMID: 32515658 Free PMC article.
[Retrospective Observational Study on Chemical Coping].
Kessoku T, Kobayashi T, Kusakabe A, Matsuura T, Honda Y, Yoshimi A, Sukegawa A, Takeda Y, Hata C, Saito S, Miyashita Y, Arai S, Tsuchiya K, Nakajima A, Ichikawa Y. Kessoku T, et al. Among authors: kobayashi t. Gan To Kagaku Ryoho. 2019 May;46(Suppl 1):60-62. Gan To Kagaku Ryoho. 2019. PMID: 31189856 Japanese.
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).
Ozaki A, Yoneda M, Kessoku T, Iwaki M, Kobayashi T, Honda Y, Ogawa Y, Imajo K, Sakai E, Taguri M, Yamanaka T, Iwasaki T, Kurihashi T, Saito S, Nakajima A. Ozaki A, et al. Among authors: kobayashi t. Contemp Clin Trials Commun. 2019 Dec 31;17:100516. doi: 10.1016/j.conctc.2019.100516. eCollection 2020 Mar. Contemp Clin Trials Commun. 2019. PMID: 31956725 Free PMC article.
Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial.
Kamata Y, Kessoku T, Shimizu T, Kobayashi T, Kurihashi T, Sato S, Kuraji S, Aoyama N, Iwasaki T, Takashiba S, Hamada N, Kodama T, Tamura T, Ino S, Higurashi T, Taguri M, Yamanaka T, Yoneda M, Usuda H, Wada K, Nakajima A, Minabe M. Kamata Y, et al. Among authors: kobayashi t. Trials. 2020 Mar 23;21(1):291. doi: 10.1186/s13063-020-4201-y. Trials. 2020. PMID: 32293522 Free PMC article. Clinical Trial.
Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes.
Oeda S, Takahashi H, Imajo K, Seko Y, Kobayashi T, Ogawa Y, Moriguchi M, Yoneda M, Anzai K, Irie H, Sueoka E, Aishima S, Kage M, Itoh Y, Eguchi Y, Nakajima A. Oeda S, et al. Among authors: kobayashi t. Hepatol Res. 2020 Jul;50(7):831-839. doi: 10.1111/hepr.13508. Epub 2020 May 13. Hepatol Res. 2020. PMID: 32337818
Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study.
Ogawa Y, Kobayashi T, Honda Y, Kessoku T, Tomeno W, Imajo K, Nakahara T, Oeda S, Nagaoki Y, Amano Y, Ando T, Hirayama M, Isono O, Kamiguchi H, Nagabukuro H, Ogawa S, Satomi Y, Saigusa Y, Takahashi H, Hyogo H, Yoneda M, Saito S, Yamanaka T, Aishima S, Eguchi Y, Kage M, Chayama K, Nakajima A. Ogawa Y, et al. Among authors: kobayashi t. Hepatol Res. 2020 Aug;50(8):955-965. doi: 10.1111/hepr.13528. Epub 2020 Jul 15. Hepatol Res. 2020. PMID: 32455496
Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study.
Ozaki A, Kessoku T, Iwaki M, Kobayashi T, Yoshihara T, Kato T, Honda Y, Ogawa Y, Imajo K, Higurashi T, Yoneda M, Taguri M, Yamanaka T, Ishiki H, Kobayashi N, Saito S, Ichikawa Y, Nakajima A. Ozaki A, et al. Among authors: kobayashi n, kobayashi t. Trials. 2020 Jun 1;21(1):453. doi: 10.1186/s13063-020-04385-0. Trials. 2020. PMID: 32487150 Free PMC article.
The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota.
Misawa N, Higurashi T, Takatsu T, Iwaki M, Kobayashi T, Yoshihara T, Ashikari K, Kessoku T, Fuyuki A, Matsuura T, Ohkubo H, Usuda H, Wada K, Naritaka N, Takei H, Nittono H, Matsumoto M, Honda A, Nakajima A, Camilleri M. Misawa N, et al. Among authors: kobayashi t. Aliment Pharmacol Ther. 2020 Sep;52(5):821-828. doi: 10.1111/apt.15950. Epub 2020 Jul 20. Aliment Pharmacol Ther. 2020. PMID: 32687674 Clinical Trial.
14,904 results
You have reached the last available page of results. Please see the User Guide for more information.